GW Communications

GW Pharmaceuticals is a pioneering biopharmaceutical company recognized as the global leader in the development and commercialization of cannabinoid-based therapeutics. The company's flagship product, Epidiolex (cannabidiol), was the first plant-derived cannabinoid medicine to receive FDA approval, specifically for the treatment of rare, severe forms of childhood-onset epilepsy including Dravet syndrome and Lennox-Gastaut syndrome. GW also developed Sativex (nabiximols), the world's first plant-derived cannabinoid prescription drug, approved in over 25 countries for the treatment of spasticity associated with multiple sclerosis. In 2021, the company was acquired by Jazz Pharmaceuticals for approximately $7.2 billion, significantly expanding Jazz's neuroscience portfolio. GW's research continues to leverage its proprietary cannabinoid platform to explore treatments for a wide range of conditions, including autism, schizophrenia, and neonatal hypoxic-ischemic encephalopathy.